Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells.
about
Human UMP-CMP kinase 2, a novel nucleoside monophosphate kinase localized in mitochondriaAssessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitorsAntiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues.Antiviral L-nucleosides specific for hepatitis B virus infectionThe roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunctionAn analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitorsHigh-dose clevudine impairs mitochondrial function and glucose-stimulated insulin secretion in INS-1E cells.In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus.In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.Anti-HBV specific beta-L-2'-deoxynucleosides.Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?Design, synthesis, and in vitro and in vivo biological studies of a 3'-deoxythymidine conjugate that potentially kills cancer cells selectivelyNonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B3'-Azido-3'-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity.Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.Changing patterns in the neuropathogenesis of HIV during the HAART era.Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapyAbsence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.Inhibition of hepatitis B virus by a novel L-nucleoside, beta-L-D4A and related analogues.Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.Transgenic hepatitis B: a new model of HBV infection.Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.Integration of cellular bioenergetics with mitochondrial quality control and autophagy.Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments.Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction.AZT 5'-Phosphonates: Achievements and Trends in the Treatment and Prevention of HIV InfectionLong term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity.Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects.Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling.Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors.Premature and accelerated aging: HIV or HAART?Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophyCharacterization of hepatitis B virus inhibition by novel 2'-fluoro-2',3'-unsaturated beta-D- and L-nucleosides.Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys.Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells.Deficit in cytochrome c oxidase activity induced in rat sperm mitochondria by in vivo exposure to zidovudine.Beyond the polymerase-γ theory: Production of ROS as a mode of NRTI-induced mitochondrial toxicity.
P2860
Q24300329-49A79D69-02C8-4F71-9737-87D715FB142EQ24536268-1A69B174-C6FD-4CA4-AE33-B37AD0A8A56CQ27472805-64475214-B612-488C-BA4B-5DCA6416E85BQ28345251-FC667465-D497-4A16-8AAB-D4E22CCF5276Q28386344-C3F52DE2-CA73-4FBA-84B9-E24E0A196384Q28474361-FFB42563-B692-4F94-A9BA-3625F17BCE06Q34121999-14DC513B-6197-4ED5-928A-D23BBAE7A771Q34289964-187487D9-65CF-4821-8CE0-F20A5749C891Q34352006-AFE5CB24-66FC-453F-8DC7-5E50A0295785Q34373564-A810774E-5452-48C3-9E7D-A155935E9F88Q34464649-E6CFB8C4-DC38-40B6-82F5-B64C416EDAB0Q34540458-C24968B2-ECF4-4444-86C8-1E6CDE0C52D0Q34591879-6674D354-438C-4305-BA67-4A4E735F5C49Q34652444-4D679AC5-962E-4D0A-BBB0-864A67158DB6Q34932672-56DA7EEE-184D-4425-90F0-BFC8877395CFQ35126422-8768548C-4033-4E3E-90A5-7AE0BE5C8078Q35586645-23B70B4B-3011-49C2-A53B-9A699CF2FADEQ35879021-7FD8C6D3-5C19-46A5-81B9-3D414211C707Q36178977-C913E530-DFB6-41D9-A3F5-F60F43BCA591Q36313228-97926D75-AFB0-4BE7-926B-BE7C485CF84BQ36390147-BB2F2A3F-7439-40E7-88C2-D9520739BE08Q36521414-E8D07A65-56F2-4895-BB7A-0F4AFDDC37D1Q36675381-6F4EB198-5C84-4127-8753-3C321F6C8294Q36880847-F8E47F42-B479-465B-933B-2622F8703581Q37270571-17A00315-8BF5-443F-8616-78C54B4B49E5Q37358511-0A68FC76-E6B0-4CD3-95E5-3EA737AC9B43Q37634512-4C0D9663-C709-4CD1-927A-7877FEB3B652Q37727959-AF5E2937-B0E9-4803-BFF5-A6EB3140FD48Q38326199-18AF50D2-5DB7-4795-AD5D-048A6C8ECAE2Q38568978-26678EB0-056F-4CEE-BC99-7911A244A51FQ39474417-612ECC5C-7A61-4766-87FD-4C3914F0EB60Q39739985-A7E8C8D0-221E-44E8-9102-A655CDA861F6Q40400203-8193ED18-DEF7-480F-80E4-93D1A5176EBBQ41126428-56BDAA8E-6768-49B4-AD53-54401BF312E5Q41883516-1B66E596-8D1B-4B36-8466-F7AF554C9254Q43787817-2E328E0B-0C50-49DE-B45C-F23E2F337020Q43787821-179E5409-347D-40D2-B17E-8ED0F090245FQ44297096-6C1FA760-B1EB-4E61-8E37-51BCCA3E66C4Q44597380-89E9CAFC-2087-48CC-9992-4EB861DD7F7DQ44797235-9AC9C853-C4B6-4869-950D-11ADB420FA0B
P2860
Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Differential effects of antire ...... drial function in HepG2 cells.
@ast
Differential effects of antire ...... drial function in HepG2 cells.
@en
type
label
Differential effects of antire ...... drial function in HepG2 cells.
@ast
Differential effects of antire ...... drial function in HepG2 cells.
@en
prefLabel
Differential effects of antire ...... drial function in HepG2 cells.
@ast
Differential effects of antire ...... drial function in HepG2 cells.
@en
P2093
P2860
P1476
Differential effects of antire ...... drial function in HepG2 cells.
@en
P2093
Darley-Usmar VM
Pan-Zhou XR
Sommadossi JP
P2860
P304
P356
10.1128/AAC.44.3.496-503.2000
P407
P577
2000-03-01T00:00:00Z